The abstract is read at the publisher; the summary is JClub's.
TIGIT+ CD8+ T cells in melanoma patient blood are linked to tumor-reactive cytotoxicity and a TIGIT-associated transcriptional program, enabling detection beyond PD-1.
- Why it matters: Non-invasive monitoring of systemic tumor-reactive CD8+ T cells is needed, but functional and molecular identification in patient blood is difficult.
- What they did: The study functionally validated TIGIT as a surrogate marker, tested cytotoxicity against autologous tumor cells, profiled clonotypes and epigenetic features, and used longitudinal blood sampling during immune checkpoint inhibition plus paired single-cell RNA/TCR data.
- The result: TIGIT+ CD8+ T cells showed robust tumor killing irrespective of PD-1 co-expression, were associated with intratumoral T cell repertoires and antigen-experienced hallmarks, increased in clinical responders, and the TIGIT program enabled robust detection of circulating tumor-reactive clones.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.